| Zacks Company Profile for Immunovant, Inc. (IMVT : NSDQ) |
|
|
| |
| • Company Description |
| Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.
Number of Employees: 362 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $16.16 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,464,419 shares |
| Shares Outstanding: 174.32 (millions) |
| Market Capitalization: $2,816.96 (millions) |
| Beta: 0.45 |
| 52 Week High: $32.10 |
| 52 Week Low: $12.72 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
6.32% |
4.45% |
| 12 Week |
1.89% |
-7.45% |
| Year To Date |
-34.76% |
-39.44% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Eric Venker - Chief Executive Officer
Frank M. Torti - Executive Chairperson
Tiago Girao - Chief Financial Officer
Jacob Bauer - Director
Andrew Fromkin - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45258J102
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/06/25
|
|
Share - Related Items
Shares Outstanding: 174.32
Most Recent Split Date: (:1)
Beta: 0.45
Market Capitalization: $2,816.96 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.72 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.86 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 11.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/06/25 |
|
|
|
| |
